Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:


Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,129,232

« Back to Dashboard

Which drugs does patent 7,129,232 protect, and when does it expire?

Patent 7,129,232 protects ZERBAXA and is included in one NDA.

This patent has twenty-five patent family members in twenty countries.

Summary for Patent: 7,129,232
Title:Cephem compounds
Abstract: The present invention relates to a compound of the formula [I]: ##STR00001## wherein R.sup.1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R.sup.2 is hydrogen or amino protecting group, or R.sup.1 and R.sup.2 are bonded together and form lower alkylene or lower alkenylene; R.sup.3 is hydrogen or lower alkyl; R.sup.4 is ##STR00002## R.sup.5 is carboxy or protected carboxy; and R.sup.6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.
Inventor(s): Ohki; Hidenori (Osaka, JP), Okuda; Shinya (Osaka, JP), Yamanaka; Toshio (Osaka, JP), Ohgaki; Masaru (Osaka, JP), Toda; Ayako (Osaka, JP), Kawabata; Kohji (Osaka, JP), Inoue; Satoshi (Takata-gun, JP), Misumi; Keiji (Takata-gun, JP), Itoh; Kenji (Takata-gun, JP), Satoh; Kenji (Takata-gun, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP) Wakunaga Pharmaceutical Co., Ltd (Osaka, JP)
Application Number:10/695,895
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,129,232
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,129,232

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHODS OF TREATING BACTERIAL ILLNESSES ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,129,232

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2002952355Oct 30, 2002
Australia2003904813Sep 4, 2003

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.